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AbstractmIn this study we have specifically investigated
the participation of T cells in the cytotoxic activity of
peripheral blood lymphocytes (PBL) activated by interleu-
kin-2 (IL-2, 50 U/ml) alone or in combination with an anti-
CD3 mAb (BMA030, 10 ng/ml, IgG2a). Purified CD3+ T
cells, incubated in the presence of the anti-CD3 mAb for 4
days, mediated a cytotoxic activity against HL60 and U937
tumor cell lines. Several findings suggested the involve-
ment of a redirected-cytotoxicity phenomenon, since the
lytic process was restricted to target cell lines bearing the
high-affinity Fc g receptor (Fc g RI) and T lymphocytes
stimulated by IL-2 alone did not lyse these cell lines.
Furthermore, anti-CD3 mAb F(ab9)2, anti-CD3 IgG1
(UCHT1), phytohemagglutinin or staphylococcal entero-
toxin A did not induce a similar cytotoxic activity in T
lymphocytes. The cytotoxic process occurred in the pres-
ence of a very low level of anti-CD3 antibodies (in the
nanomolar range). The cytotoxic activity of T cells stimu-
lated by IL-2 or by IL-2 + BMA030, against OVCAR-3
cells (MOv18+ ovarian tumor cell line), was also compared
in the presence of a bispecific antibody (OC/TR, anti-CD3
· MOv18). The stimulation by IL-2 + BMA030 induced
approximately a twofold higher cytotoxic activity than
IL-2-activated T cells. This could be related to the state
of activation of effector cells stimulated by IL-2 +
BMA030, since the phenotypic analysis showed an in-
creased proportion of T cells expressing several activa-
tion/differentiation markers (CD25, HLA-DR, CD45R0,
adhesion molecules). These findings could be applied to
the design of therapeutic protocols using anti-CD3
· antitumoral bispecific antibodies.
Key wordsmAnti-CD3 mAb ? Redirected cytotoxicity ? Fc g
receptor (Fcg R) ? Bispecific antibody ? Activation
Introduction
A large number of reports have addressed the cytotoxic
properties of lymphokine-activated killer cells (LAK cells)
generated by short-term culture of peripheral blood lym-
phocytes (PBL) with interleukin-2 (IL-2) [10, 24, 26, 28].
Despite interesting in vitro properties, the clinical efficacy
of LAK cell therapy in cancer-bearing patients has not been
satisfactory in most cases [55, 56]. Essentially these un-
satisfactory results might be related to the fact that LAK
cells belong to the natural killer (NK) subset [46, 50].
Parmiani [49] has even proposed that successful adoptive
therapy with LAK cells could depend on the recruitment of
activated host T lymphocytes. Therefore, it would be
interesting to evaluate alternative protocols of immunother-
apy based on T cells, rather than NK cells. Moreover, the
use of bispecific antibodies that bind both the T cell
receptor (TCR) complex and a target cell-surface molecule
has renewed the interest in the development of T cell
stimulation protocols [5, 6, 20, 37].
Soon after the production of the first murine monoclonal
antibodies directed against the human TCR-CD3 complex,
a large number of studies concentrated on the effects of
these reagents on the activation, proliferation and cytotoxic
differentiation of T cells [15, 45, 48]. In view of the
important secretion of cytokines (including IL-2) induced
by these antibodies [11, 17, 19, 51] it was proposed that
anti-CD3 mAb could participate in the induction of a non-
MHC-restricted LAK-like cytotoxic activity by T cells [12].
Recently, two groups [16, 43] have demonstrated the
induction of antitumor activity using anti-CD3 mAb, in
an in vivo murine model. In these studies, the injection of
anti-CD3 [16] alone or in combination with IL-2 [43] in
tumor-bearing mice induced the reduction [43] or the
eradication [16] of tumor metastasis. However, very few
studies carefully evaluated the antitumoral activity of T
cells stimulated by anti-CD3 mAb with sorted lymphocyte
subsets, most likely because classical sorting procedures are
laborious and interfere with the function of cytotoxic
effectors. We recently described an original protocol for
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the positive selection of T cells using a magnetic cell sorter
(MACS), magnetic beads and F(ab9)2 anti-CD3 mAb. When
performed at the effector stage this procedure was shown
not to modify the function of T cells [29]. Therefore, we
used this technique to characterize TCR-dependent and
TCR-independent (LAK-type) cytotoxic activity of T cells
after short-term culture of PBL with IL-2 compared with
that with IL-2 + anti-CD3 mAb.
In this study, we have attempted to define the type of
effector cells generated by the stimulation of human PBL
with anti-CD3 mAb and to characterize their antitumoral
activity. The cultured cell populations were sorted into T
cells and non-T cells or NK cells and non-NK cells by using
MACS or flow-cytometry sorting (FACS) procedures.
Several aspects of the cytotoxic phenomenon were
considered, including the generation of serine esterase
(granzyme) activity [57] and the direct lysis of tumor cell
lines detected by a 51Cr-release assay. On the basis of our
data, we suspected that residual anti-CD3 mAb at the
surface of activated T cells were involved in the lysis of
Fc-receptor-positive (Fcg R+) tumor cell lines. Similarly, the
cytotoxic potential of activated T cells was also tested in the
presence of bispecific anti-CD3 · anti-MOv18 mAb,
which can bridge T cells to Fc g R– tumor cell lines bearing
the MOv18 epitope.
Overall the results suggest that cells cultured with anti-
CD3 mAb provide an optimal activation of T cells com-
pared with culture with IL-2 alone. Nevertheless, the short-
term cytotoxic process strictly requires binding to the tumor
cell either by a bispecific mAb or by residual membrane
mAb.
Material and methods
Preparation and culture of PBL
Healthy donors were used as a source of PBL (Centre de transfusion de
Lie`ge, Belgium). The lymphocytes were prepared by centrifugation on
Lymphoprep (Nycomed, Oslo, Norway), washed three times and
counted. The culture medium consisted of RPMI-1640 medium
(Gibco BRL, Gent, Belgium) supplemented with 1% non-essential
amino acids (Gibco), sodium pyruvate (1 mM Gibco), 30 U/ml
penicillin/streptomycin (Gibco) and 5% pooled heat-inactivated
human AB serum. Cells were cultured (1.25 · 106 cells/ml) in the
presence of 10 ng/ml anti-CD3 mAb (BMA030, IgG2a; Behringwerke,
Marburg, Germany) and 50 U/ml human recombinant (r)IL-2 kindly
provided by Glaxo Institute for Molecular Biology (AG, Gene`ve,
Switzerland). For some experiments, the cell were cultured with
other anti-CD3 mAb (UCHT1, IgG1, Immunotech, Marseille, France;
SPVT3 F(ab9)2, Zymed, San-Francisco, Calif.; BMA033, IgG3, Beh-
ringwerke) or in the presence of staphylococcal enterotoxin A (10 ng/
ml, Sigma, Bornem, Belgium) or in the presence of phytohemagglu-
tinin (PHA; 0.1%, Difco, Mich).
Cell separation
The magnetic cell separation was previously described [29]. Briefly,
the cells were incubated in phosphate-buffered saline (Gibco) with a
biotinylated anti-CD3 mAb F(ab9)2 (Zymed) for 20 min. The cells were
then incubated with fluorescein-isothiocyanate(FITC)-labelled strepta-
vidin (Boehringer Mannheim, Brussels, Belgium). Finally, the cells
were incubated in the presence of 100 m l 1/100 diluted biotinylated
magnetic beads (Miltenyi Biotec GmbH, Bergisch-Gladbach, Ger-
many) for 5 min. The cell sorting was done with the MACS instrument
(Becton Dickinson, Erembodegem, Belgium) [38]. The purity of the
positive and negative cell fractions were respectively verified by flow
cytometry (FACStar+, Becton Dickinson). When needed, further pur-
ification was performed by a flow-cytometry cell sorter (FACStar+).
For some experiments NK cells (CD56+ and CD16+ cells) were
depleted by flow-cytometry cell sorting.
Cell lines
The tumor cell lines used in this study are K562 [35], U937 [59], Daudi
[30], HL60 [14], CESS [42], LY, Nalm-6 [27], Molt-3, Molt-4 [39],
Jurkat [62], A431 [22], OVCAR-3 [25] and CK2 [23]. The cell lines
were cultured in RPMI-1640 medium with the exception of CK2,
which was maintained in Dulbecco’s modified Eagle’s medium
(Gibco). Both media were supplemented with 10% fetal calf serum
(Gibco).
Cytotoxicity assays
The 51Cr-release cytotoxic assays were performed in 96-well V-bottom
plates using 5000 51Cr-labelled (Amersham, Belgium) tumor targets/
well. Six serial dilutions of effector cells were prepared (effector
cell:target ratios, E:T, 20:1–0.75:1). Plates were centrifuged for
6 min at 400 g to ensure cell contact and incubated for 4 h at 37 ° C.
Samples of 100 m l supernatant were then recovered from each well and
the radioactivity was measured in a g counter (Cobra auto-gamma
Packard, Downers Grove, Ill.). Maximum chromium release was
obtained by adding 100 m l detergent (RBS 10%, Chemical Products,
Belgium) to 100 m l of target cell suspension and spontaneous release
was given by incubation of target cells without effector cells. The
percentage of target lysis was calculated as previously described [29].
For some experiments, OC/TR F(ab9)2 bispecific antibody (kindly
provided by Centocor, Leiden, The Netherlands) (100 ng/ml) was
added to the target cells 30 min before the cytotoxic assay. The
bispecific antibody OC/TR recognizes CD3 and a folate-binding
protein, a molecule overexpressed in about 90% of ovarian carcinomas
[36]. Serine esterase activity was measured using N-benzyloxycarbo-
nyl-L-lysine-thiobenzyl-ester esterase (BLT assay), as previously de-
scribed [58].
Immunofluorescence and flow cytometry
Double and triple staining were performed with antibodies directed
against CD2 (T11 FITC), CD3 (IOT3 FITC), CD4 (IOT4 FITC),
CD45R0 [phycoerythrin(PE)-labelled] and CD25 (PE) from Dako
(Golstrup, Denmark). The anti-CD3 (PerCP), anti-CD28 (PE), anti-
CD45RA (FITC), anti-CD11a (LFA-1 FITC), anti-CD16 (Leu11c PE),
anti-CD56 (PE), anti-CD57 (FITC) and anti-HLA-DR (FITC) were
purchased from Becton Dickinson. The anti-CD8 (PE) and anti-CD19
(PE) were obtained from Immunotech. The antibodies directed against
the Fcg RI (CD32, 32.2 FITC) and the Fcg RII (CD64, IV.3 FITC) were
purchased from Medarex (West Lebanon, N.H.). A goat anti-mouse Ig,
FITC-labelled (Immunotech), was used to detect on the cell surface the
presence of BMA030 used for the stimulation. The cells were analyzed
for fluorescence intensity on a FACStar+ (Becton Dickinson).
Statistical analysis
The data were analyzed using Student’s t-test (Instat Mac 2.01 soft-
ware, GraphPad, San Diego, Calif.).
Results
Lymphocyte phenotype obtained after activation
with IL-2 or with IL-2 + BMA030
To determine the cell populations and the state of cell
activation obtained after stimulation by IL-2 or by IL-2 +
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BMA030, the cell phenotype was characterized by a panel
of antibodies. A higher percentage of T lymphocytes (CD2+
CD3+) was obtained in the IL-2 + BMA030 culture condi-
tions, compared to what was observed with IL-2 alone
(Table 1). The presence of BMA030 in the culture medium
also induced a higher percentage of CD25+ (68% versus
13%), HLA-DR+ (38% versus 14%), CD45R0+ (63% versus
41%) and CD28+ (86% versus 74%) cells compared to that
observed with IL-2 alone (Table 1). Moreover, an increased
frequency of T cells expressing a high density of LFA1
(CD11ahigh, 61% versus 30%) and CD2 (CD2high, 55%
versus 12%) was obtained when lymphocytes were stimu-
lated with IL-2 + BMA030.
Comparison of cytotoxic activity of T cells stimulated with
IL-2 with that of cells treated with IL-2 and anti-CD3 mAb
The lysis of K562 and Daudi cells, which are classical
target cells for NK and LAK cell activities, was similar with
lymphocytes cultured for 4 days with either IL-2 or IL-2 +
BMA030, but the stimulation by IL-2 + BMA030 induced a
higher cytotoxic activity against HL60 and U937 than did
IL-2 alone (P50.005 for HL60 and P50.01 for U937)
(data not shown). In parallel, a higher increase of serine-
esterase activity was observed in the presence of both IL-2
and BMA030 compared to the value for IL-2 stimulation
(P$0.05) or for unstimulated cells (P$0.01) (data not
shown). To determine the respective participation of NK
cells and T lymphocytes in this lytic activity, the mixed
population was sorted for CD3 expression before the
cytotoxicity assay. According to a previously published
protocol [29], we used MACS alone or MACS + FACS to
achieve a purity superior to 95% in both CD3+ and CD3–
cell fractions. The majority of CD3– cells were NK cells as
assessed by the presence of cell-surface CD16 and/or CD56
(data not shown).
To determine more accurately the spectrum of cytotoxic
activity displayed by PBL activated by IL-2 + anti-CD3, a
panel of ten hematopoietic tumor cell lines was used
(Table 2). The CD3- cells killed all cell lines, whereas the
CD3+ T cells were poorly cytotoxic to most of the cell lines,
except for HL60 and U937. By contrast, after stimulation
with IL-2 alone, the CD3+ T cells did not show any
significant cytotoxic activity against these target cell lines
(data not shown). Similar results were obtained when the T
cell fraction was purified by negative selection, showing
that the sorting procedure did not interfere with the cyto-
toxic properties of the effectors (data not shown).
Role of membrane-bound mAb in the cytotoxic activity
induced in culture with IL-2 and anti-CD3 mAb
We then checked for the presence of Fc g R on the target
cells. Interestingly, HL60 and U937 were both positive for
Fc g RI, a receptor with a high affinity for murine IgG2a
antibodies (Table 1). This observation suggested that resi-
dual BMA030, an IgG2a antibody, on the cultured lympho-
cytes may have acted as a bridge between activated T cells
and Fc g RI-bearing target cells, thus being responsible for
redirection of the cytotoxic activity against the targets.
Accordingly, when PBL were cultured with an anti-CD3
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Table 1mCell-surface phenotype. Results are means % + SD of
positive cells from 5–36 independent experiments. P values were
calculated by comparing the results of interleukin-2 (IL-2) and IL-2 +
anti-CD3 mAb stimulation. CD11ahigh, CD2high cells expressing a high
density of cell-surface marker






CD2 83+ 5 84+ 6 93+ 5 0.0015
CD3 78+ 7 79+ 7 85+ 5 0.0004
CD25 5+ 3 13+ 5 68+10 0.0001
CD28 76+ 4 74+ 4 86+ 5 0.0315
CD3+ DR+ 6+ 3 14+ 7 38+13 0.0007
CD45R0 40+11 41+10 63+11 0.0001
CD45RA 63+11 67+10 49+17 0.0001
CD11ahigh 22+12 30+13 61+13 0.0001
CD2high 4+ 4 12+ 6 55+17 0.0060
Table 2mCytotoxic activity of lymphocytes (unsorted and sorted cells)
stimulated by IL-2 + anti-CD3. Cells were cultured for 4 days in the
presence of IL-2 + anti-CD3 mAb (BMA030) and sorted into CD3+
and CD3– cell populations. The cytotoxic activity was determined in a
4-h 51Cr-release assay against ten hematopoietic tumor cell lines with
different patterns of Fc g receptors, their pattern being determined by
fluorescein-isothiocyanate-labelled antibodies (Fc g RI and Fc g RII) or
phycoerythrin-labelled antibody (Fc g RIII). The data are shown for an
E : T of 20 : 1. The results represent means + SD of 3–6 independent
experiments. P values were calculated by comparing the cytotoxic
activity of CD3+ and CD3– cells
Fcg R Cytotoxicity (%)
Cell lines I II III Unsorted cells CD3– cells CD3+ cells P
K562 – + – 47+16 91+12 9+2 0.0003
Daudi – + – 65+16 75+11 8+6 0.0001
Ly – – + 19+ 9 30+11 5+2 0.0260
Cess – – + 17+12 32+22 3+3 0.0800
Nalm-6 – + – 15+ 1 54+ 8 13+6 0.0290
Jurkat – – – 67+30 76+ 1 13+3 0.0250
Molt-3 – – – 35+ 6 53+ 9 3+1 0.0160
Molt-4 – – – 27+17 59+ 1 2+1 0.0001
U937 + + – 57+13 62+ 1 56+1 0.2500
HL60 + + – 55+ 3 56+17 45+4 0.3000
F(ab9)2 fragment or with a non-mAb TCR ligand such as
staphylococcal enterotoxin A or PHA, the sorted T cells did
not display any significant cytotoxic activity against HL60
and U937 (less than 10% lysis). Similarly, the use of an
anti-CD3 mAb (UCHT1, IgG1) that has a poor affinity for
Fc g RI did not induce a strong cytotoxic activity against
these targets (data not shown). By contrast, stimulation with
an anti-CD3 IgG3 mAb, which has the same affinity as
IgG2a mAb for Fc g RI, induced similar cytotoxicity to
BMA030 (IgG2a). Despite this evidence for a participation
of the anti-CD3 mAb in the effector stage of the lytic
process, only a small amount of residual anti-CD3 mAb (in
the nanomolar range) could be detected on activated T cells
by a goat anti-mouse Ig mAb (Fig. 1). In fact, we observed
that, in most experiments, the amount of membrane mAb
molecules on our effectors corresponded to a standard
staining assay performed with a working concentration of
0.6 ng/ml mAb (Fig. 1).
Comparison of OC/TR bispecific mAb retargeting
of T cells stimulated with IL-2 with that of cells stimulated
with IL-2 + BMA030
The hypothesis that anti-CD3-stimulated PBL could kill
their target through a “redirected” pathway, even in the
presence of low amounts of mAb, led us to investigate the
activity of these cells in the presence of bispecific antibod-
ies directed against both CD3 and a tumor-specific antigen.
OC/TR is a monoclonal bispecific antibody, which recog-
nizes both CD3 and a folate-binding protein (MOv18), a
cell-surface molecule overexpressed on ovarian tumors. We
determined whether the short-term culture with anti-CD3
mAb plus IL-2 could be more efficient than IL-2 alone in
generating effector cells against the MOv18+ OVCAR-3
tumor cell line. The MOv18– A431 tumor cells were used
as negative controls.
After 4 days of culture in the presence of IL-2 or IL-2 +
BMA030, the CD16+ and CD56+ cells were depleted from
the cell population to eliminate NK activity. In three
independent experiments, a specific cytotoxic activity
could be detected against the MOv18+ OVCAR-3 tumor
cell line after addition of F(ab9)2 bispecific antibody OC/TR
in the cytotoxic assay (Fig. 2). Retargeted cytotoxicity was
more pronounced after stimulation with IL-2 + BMA030
(P50.05) (Fig. 2). The stimulation of T cells by PHA + IL-
2 was not as effective in generating retargeted cytotoxicity,
as was the stimulation by IL-2 + BMA030 (data not
shown).
Discussion
This report illustrates several findings regarding T cell
activation and antitumor cytotoxicity. (a) Short-term culture
of PBL with BMA030, in the presence of a concentration of
IL-2 sufficient to induce LAK cells [1, 4, 21, 60, 63],
enhanced the differentiation of cytotoxic T cells devoid of
any LAK-like activity (as shown by the absence of lytic
activity against Daudi and K562). (b) The cytotoxic activity
of T cells observed in a 4-h chromium-release assay, was
strictly dependent on the presence of Fc g RI on the target
cells; interestingly the effect was obtained with a very low
amount of anti-CD3 mAb, supposedly in the nanomolar
range, in contrast to previously published models of redir-
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Fig. 1A–HmDetection of BMA030 after 4 days of culture. An
incubation of peripheral blood lymphocytes with different concentra-
tions of BMA030: A 10 ng, B 2.5 ng/ml, C 0.6 ng/ml, D 0.05 ng/ml,
was performed and the cells were run through fluorescence-activated
cell sorting to determine the minimum amount of antibody detectable
by this technique using a fluorescein-isothiocyanate (FITC)-labelled
goat anti-mouse Ig. - - - The control fluorescence. E The same cells
were cultured for 4 days in the presence of interleukin-2 + BMA030
and loaded with FITC-labelled goat anti-mouse Ig. F, G and H Three
other independent experiments on anti-CD3 mAb detection after 4 days
of culture
ected cytotoxicity [8, 33, 44, 53, 64]. (c) Accordingly, T
cells from cultures activated with IL-2 + BMA030
mediated a higher bispecific mAb-dependent cytotoxicity
than their counterparts cultured with IL-2 alone.
We formally demonstrated that, in the presence of a
“LAK-inducing” concentration of IL-2, the cytotoxic ac-
tivity induced in cultures of T lymphocytes with an anti-
CD3 mAb, during a 4-hour 51Cr-release assay, was strictly
of the “antibody-redirected” type since only target cell lines
bearing Fc g RI (high-affinity receptor) (HL60 and U937) [2]
(and personal results) were lysed. As very few BMA030
molecules were detected on the cell surface at the end of the
culture, it is likely that the cytotoxic process did not require
a large number of anti-CD3 mAb molecules, unlike results
previously reported with other models of redirected cyto-
toxicity [13, 33, 44, 53]. Furthermore, there was no corre-
lation between the level of the cytotoxicity and the level of
detection of BMA030. One could argue that the sensitivity
of the detection assay, based on FITC-conjugated goat anti-
mouse-Ig mAb was not sufficient to estimate the amount of
antibody required to induce the lysis. We observed that, in
most experiments, the amount of membrane mAb mole-
cules on our effectors was in the nanomolar range, which is
far below the dose usually recommended to obtain redir-
ected cytotoxicity. Furthermore, with a more sensitive assay
that has been reported to detect as few as 400 molecules/
cell [65], no additional BMA030 was detected in any of the
experiments (results not illustrated).
The cytotoxicity mediated by the bispecific antibody is
very similar to the anti-CD3-redirected cytotoxicity, except
that the lysis is not limited to Fc g R+ target cells. This type
of cytotoxicity increases when activated effector cells are
used [40]. We have demonstrated that stimulation of PBL
with IL-2 + BMA030 increases the cytotoxicity against
folate-binding protein FBP+ target cells following retarget-
ing via OC/TR bispecific antibody, in contrast to the
cytotoxicity observed with IL-2-activated lymphocytes.
Other authors have also demonstrated the advantages of
anti-CD3 + IL-2 stimulation compared to stimulation with
IL-2 alone for the enhancement of cytotoxic activity
mediated by other bispecific antibodies [3]. However, in
contrast to our study, the effectors T cells were not sorted,
thus the contribution of NK cells (LAK activity) to the
cytotoxic activity was not known. Lamers et al. [31]
observed that the induction of OC/TR-antibody-directed
cytotoxicity was more rapid after anti-CD3 mAb activation,
than after PHA activation of lymphocytes.
In addition to the antibody/antigen interaction induced
by the bispecific mAb, adhesion molecules could be in-
volved in the binding of the effector cell to the tumor cell.
In IL-2 + BMA030 cultures, the cells had an increased
expression of adhesion molecules such as LFA1 (CD11a)
and CD2 previously described to be involved in redirected
cytotoxicity. For example, an interaction between LFA-1
and ICAM was found to be required for cytotoxic activity
induced by an anti-(epidermal growth factor, EGF, recep-
tor)/anti-CD3 bispecific mAb [18]. In fact, pretreatment of
effector cells by anti-LFA1 mAb significantly inhibited
cytolysis of all types of EGF-receptor-positive tumor
cells. The cell-surface phenotype was also studied and a
larger proportion of cells stimulated by IL-2 + BMA030
had an activated phenotype and a higher expression of
CD28. All these properties (expression of adhesion mole-
cules, activated/memory phenotype) could be associated
with a lowered threshold for triggering of lysis after the
interaction with the tumor cell. Moreover the culture con-
dition IL-2 + BMA030 generated more effector T cells with
a memory phenotype that has been shown to be associated
with redirected cytotoxicity in a previous report [54].
Several investigations have already shown an increase of
CD3+ [40], CD25+ [48], CD3+HLA-DR+ [47], and CD2+high
[9] cells in the presence of IL-2 + anti-CD3. Percentages of
positive cells obtained in these studies were similar to or
smaller than ours. But, their culture conditions were differ-
ent from ours since purified T cells were cultured or the
anti-CD3 was removed from the culture medium by wash-
ing the cells at least 24 h before the cytotoxic assay.
The cytotoxic potential of effector cells can also be
accessed by performing the serine esterase assay (BLT
assay) or the tumor growth inhibition assay (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide,
MTT assay). Preliminary results obtained using a BLT
assay on unpurified lymphocytes stimulated by IL-2 or
IL-2 + BMA030 showed that higher serine esterase activity
was observed after culture in the presence of IL-2 +
BMA030. Though the production of serine esterase after
culture in the presence of IL-2 or anti-CD3 is well docu-
mented [7, 13, 32, 34], up to now comparison of the two
culture conditions using the BLT assay has only been
reported in a murine model [61]. In that model, the
production of serine esterase was similar for the two culture
conditions. Concerning the MTT assay, we also observed a
higher tumor growth inhibition with lymphocytes stimu-
lated by IL-2 + anti-CD3. This higher cytotoxic potential
could be related to an increased production of cytokines
interferon g (IFNg ) and tumor necrosis factor a (TNFa )
[52], as suggested by our analysis of PBL culture super-
373
Fig. 2mCytotoxic activity in the presence of bispecific antibody (OC/
TR). After 4 days of culture with IL-2 or IL-2 + BMA030, natural killer
cells were depleted and a cytotoxic assay was performed against A431
an OVCAR-3 tumor cell line in the presence or absence of the
bispecific antibodies (OC/TR). The means +SD of three independent
experiments are represented. E:T = 20:1
natants. This hypothesis is correlated with a previous study
where stimulation by IL-2 + BMA030 induced a higher
production of TNFa and IFNg than did stimulation with
IL-2 [41].
In conclusion, these experiments have demonstrated the
advantages of the combined use of anti-CD3 and IL-2 to
induce an optimal differentiation of cytotoxic T cells
capable of killing tumor cells in the presence of bispecific
antibodies. Our results have a potentially interesting appli-
cation in the design of immunotherapy protocols based on
anti-CD3 · antitumor bispecific antibodies.
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